3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF Russian patent published in 2024 - IPC C07D401/12 C07D401/14 A61K31/506 A61P35/00 A61P35/02 

FIELD: chemistry.

SUBSTANCE: present invention relates to a compound of formula (II), a pharmaceutically acceptable salt thereof, a tautomer, a geometric isomer or an optical isomer, ,

use thereof and a pharmaceutical composition. In formula II, Y is ; mX is selected from a group consisting of , where the N atom bonded to R₁₂ is bonded to the pyrimidine ring; ring A is selected from a group consisting of the following groups, unsubstituted or substituted with one or more halogens: C_5-6 cycloalkyl, 3–6-membered heterocycloalkyl containing 1 heteroatom selected from N, monospirocyclyl and monospiroheterocyclyl containing 1 heteroatom selected from N, where said monospirocyclyl is selected from 4-member/4-member, 4-member/5-member and 4-member/6-member ring, wherein said monospiroheterocyclyl is selected from 4-member/4-member, 4-member/5-member and 4-member/6-member ring, wherein the number of ring atoms in each ring includes the number of spiroatoms; each of R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₁₁ and R₁₂ in each case is independently selected from the group consisting of the following groups: hydrogen; n is equal to 0; R₈ is selected from a group consisting of the following optionally substituted groups: C_1-6 alkyl, C_3-10 cycloalkyl and C_6-14 aryl; Q is selected from a group consisting of the following groups: -OR₉, where R₉ is selected from the group consisting of the following groups: hydrogen, optionally substituted C_1-6 alkyl and optionally substituted C_3-10 cycloalkyl, C_2-6 alkenyl and C_2-6 alkynyl; when the group is substituted, the hydrogen atom in the substitutable position of the group is substituted with one substituent, and each substituent is independently selected from the group consisting of halogen, C_1-6 alkyl, C_3-10 cycloalkyl, C_3-10 cycloalkylsulphonyl, 3–6-member heterocycloalkyl containing 1 heteroatom selected from N, and 6-member heteroaryl containing 1 heteroatom selected from N.

EFFECT: obtaining a compound having significant inhibitory activity on PRMT5 and having a significant inhibitory effect on tumour cells.

21 cl, 4 tbl, 63 ex